Study Name: Dementia: Hallucinations and Delusions
Clinics: Blackpool and Manchester
Therapy Area: Dementia
Gender and Age: Male or Female aged 50-90 years old
Dementia is a condition that is associated with a range of symptoms, most notably a decline in cognition and memory loss. Amongst these possible symptoms are the development of delusions and hallucinations. Around 60% of people with dementia will develop delusions. Lewy body dementia is most often associated with hallucinations, but they can be present in all types of dementia, with an overall estimated prevalence of 20%. Typical treatment for these symptoms are antipsychotic medications, for example, Risperidone, Olanzapine or Quetiapine. These have a varying degree of effectiveness in reducing these distressing symptoms, reinforcing the need for a new treatment.
Pimavanserin is a new form of oral, antipsychotic medication that has been previously approved for use within Parkinson’s disease psychosis and is now in a Phase III trial at MAC Clinical Research for the treatment of dementia-related psychosis.
The aim of the trial is to primarily assess how well Pimavanserin works in reducing the delusions and hallucinations in dementia. The study itself can last up to 46 weeks and over that time period you will visit a MAC clinic, either Blackpool or Manchester (whichever is easier for yourself), 15 times.
You will be compensated £1155 for your time and commitment and reasonable travel expenses will be reimbursed or transport by taxi will be provided and your GP will be kept fully informed.
A full description of the study will be given before you decide to take part, both over the phone and during an appointment at a MAC clinic
Key Inclusion Criteria:
Aged between 50-90 years old
Diagnosis of a form of dementia
Currently has psychotic symptoms (delusions and/or hallucinations)
Key Exclusion Criteria:
Unable to attend a MAC Clinic with a project partner for the study visits
Unstable or uncontrolled medical condition
Other eligibility criteria will apply. Please contact MAC for more information.
Any other information:
Eligible patients will receive a comprehensive health screen and study participation will be in collaboration with the patient’s treating physician
£1,155 and reasonable travel expenses or transport by taxi